March 28, 2012 -- Vybion announces the availability of PharmCode for partnering. PharmCode provides precise and rapid targeting of protein-protein, dimerization, phosphorylation or allele specific intracellular events in a pharmacologically meaningful manner avoiding pleiotropic effects. Most targets have multiple interactions but PharmCode Intrabodies target single events and can assess pathway effects, pathway crosstalk and toxicity analogous to small molecules targeting the same event or interaction, unlike iRNA which affects multiple pathways by deleting or reducing gene expression. When coupled to biochemical readouts, cell-based assays and gene expression arrays, PharmCode expedites drug discovery and provides a complete picture for target validation. Vybion’s programs in Huntington’s disease, protein folding pathways and insulin resistant diabetes illustrate PharmCode capabilities.
Contacts:
Lee Henderson, Ph.D., CEO
Vybion
607-266-0860 ext 4
lhenderson@vybion.com
